Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: October 27, 2014
Purpose: Notification of the publication of a Supplementary Prospectus dated October 27, 2014, supplementing a Base Prospectus dated August 4, 2014. The document relates to GSK's £15,000,000,000 Euro Medium Term Note Programme and has been approved by the UK Listing Authority.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a regulatory notice regarding a debt issuance programme rather than a financial results report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document solely announces the availability of a Supplementary Prospectus for the Euro Medium Term Note Programme.
Guidance, Outlook, and Risks
Management Commentary: None provided in this filing.
Risks and Contingencies: The filing includes a disclaimer stating that the information in the Supplementary and Base Prospectuses may be targeted at residents of specific countries only. It warns that the information is not intended for use by persons outside these jurisdictions and that access is conditional upon compliance with these requirements.
Investor Verification Checklist
- Verify the full text of the Supplementary Prospectus and Base Prospectus via the National Storage Mechanism (NSM) or the GSK investor relations website.
- Confirm eligibility to access the prospectus based on country of residence as specified in the Base Prospectus.
- Review the terms of the £15 billion Euro Medium Term Note Programme for details on interest rates, maturity, and covenants.